Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 61-70 of 603 for hematology

Edit search filters
  1. Valemetostat Tosylate (DS-3201b), An Enhancer Of Zeste Homolog (EZH) 1/2 Dual Inhibitor, For Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

    Rochester, MN

  2. Low-Dose Selinexor And Choline Salicylate For The Treatment Of Patients With Non-Hodgkin Lymphoma Or Histiocytic/Dendritic Cell Neoplasms

    Rochester, MN

  3. Pirtobrutinib And Venetoclax With MRD Detection For Previously Untreated Chronic Lymphocytic Leukemia

    Rochester, MN

  4. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined Regimen Of Mosunetuzumab And Venetoclax In Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia

    Rochester, MN

  5. GEN3013, Epcoritamab Trial In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma EPCORE™ NHL-1

    Scottsdale/Phoenix, AZ

  6. A Novel Vaccine (EO2463) As Monotherapy And In Combination, For Treatment Of Patients With Indolent Non-Hodgkin Lymphoma

    Rochester, MN

  7. A Study Of Tyrosine Kinase Inhibitor ICP-022 In Patients With R/r B-Cell Malignancies

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study To Compare Three Chemotherapy Regimens For The Treatment Of Patients With Newly- Diagnosed Mantle Cell Lymphoma

    Jacksonville, FL, Rochester, MN

  9. Tafasitamab, Lenalidomide And Venetoclax For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma

    Rochester, MN

  10. A Study To Evaluate CC-96191 To Treat Participants With Relapsed Or Refractory Acute Myeloid Leukemia

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer